EMA's CHMP recommends Orencia in psoriatic arthritis

EMA’s CHMP recommended a label expansion for Orencia abatacept (ONO-4164IV) from Bristol-Myers Squibb Co. (NYSE:BMY) to include treatment of active psoriatic arthritis in adults for whom previous disease-modifying anti-rheumatic drug (DMARD) therapy, including methotrexate, has been inadequate and for whom additional systemic therapy is not required. The recommended indication includes monotherapy and combination therapy with methotrexate...